2seventy/BMS Halt Abecma Maintenance Trial As Landscape Evolves

The companies said they would stop enrollment in the KarMMa-9 trial of Abecma/lenalidomide due to how the treatment paradigm has shifted since the study started.

2seventy Bio, Inc. and Bristol Myers Squibb Company have hit a snag in efforts to expand the market reach of the CAR-T cell therapy Abecma (idecabtagene vicleucel) as the companies had to stop a Phase III trial of the cell therapy due to shifts in how multiple myeloma is treated.

2seventy said 25 September that it would discontinue enrollment of the KarMMa-9 trial of the BCMA-directed cell therapy as a maintenance therapy combined with lenalidomide (BMS’s Revlimid and generics) versus...

Key Takeaways

2seventy bio and BMS will stop enrollment in the KarMMa-9 trial due to evolution of the treatment landscape.
Increasing use of quadruplet therapy induction...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

30 May 2025

• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

29 May 2025

• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

29 May 2025

• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.